HUTCHMED: SANOVO Phase III data show ORPATHYS plus TAGRISSO cuts progression or death risk 44% in first-line EGFR-mutated lung cancer

HUTCHMED highlighted SANOVO Phase III data at ESMO showing ORPATHYS plus TAGRISSO cut the risk of progression or death by 44% and improved overall survival in first-line EGFR-mutated lung cancer. A China supplemental NDA is planned.

Detected & updated continuously · Source: Nebula